Table 10.

A summary of the number of dogs in each group that experienced a change in various clinical variables at the time of the onset of congestive heart failure

Categorical Variables	Treatment Group	N	Deteriorated	Unchanged	Improved	Within‐Group Paired Longitudinal Comparisons (Wilcoxon signed ranks)	Between‐Group Comparison (Mann‐Whitney)
Appetite	Placebo	69	25	44	0	<0.0001	0.26
	Pimobendan	57	27	29	1
Demeanor	Placebo	69	41	28	0	<0.0001	0.45
	Pimobendan	57	38	18	1
Exercise tolerance	Placebo	69	41	28	0	<0.0001	0.020
	Pimobendan	57	45	12	0
Fainting	Placebo	69	14	55	0	<0.0001	0.52
	Pimobendan	57	9	48	0
Respiratory effort	Placebo	69	55	14	0	<0.0001	0.074
	Pimobendan	57	52	5	0
Cough	Placebo	69	60	6	3	<0.0001	0.82
	Pimobendan	57	50	6	1
Nocturnal dyspnea or cough	Placebo	67	46	21	0	<0.0001	0.76
	Pimobendan	56	37	19	0

			Decreased	Unchanged	Increased
Body condition score	Placebo	72	26	37	9	0.0002	0.84
	Pimobendan	58	21	28	9
Heart murmur intensity	Placebo	72	8	30	34	<0.0001	0.17
	Pimobendan	58	2	23	33

P‐values for paired comparisons with the same characteristics recorded from the same dogs at baseline are given in the penultimate column.

All P‐values that appear in bold are < 0.05.